Furthermore, the CRSPR-mediated suppression of transcription elongation factor A-like 1 (TCEAL1), which is highly overexpressed in human tumors, may improve the efficacy of docetaxel in prostate cancer therapy. This evidence concerns the gene TCEAL1 and prostate cancer.